Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brazilian pilot program tests chikungunya vaccine effectiveness

NCT ID NCT07347002

ENROLLING_BY_INVITATION ⭐️ VACCINE ⭐️ Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

First seen Jan 18, 2026 · Last updated May 25, 2026 · Updated 24 times

Summary

This study looks at how well the VLA1553 vaccine prevents chikungunya disease in Brazil. Researchers will compare vaccinated and unvaccinated people who have chikungunya-like symptoms. The goal is to see if the vaccine reduces infections in a real-world setting. About 1,200 adults in areas where the vaccine is offered will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus

    Laranjeiras, Sergipe, 49060-025, Brazil

  • Fundação Faculdade Regional De Medicina De São José Do Rio Preto

    São Pedro, São Paulo, 15090-000, Brazil

  • Universidade Federal Do Ceará

    Fortaleza, Ceará, 60430-160, Brazil

  • Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras

    Belo Horizonte, Minas Gerais, 31270-901, Brazil

Conditions

Explore the condition pages connected to this study.